Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Rhea-AI Summary
Pacira BioSciences (Nasdaq:PCRX) announced that, based on preliminary results from its 2026 Annual Meeting of Stockholders, all three company director nominees — Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans — were elected to the board.
Final results will be certified and filed on Form 8-K with the SEC.
Positive
- All three Pacira director nominees preliminarily elected at 2026 Annual Meeting
Negative
- None.
News Market Reaction – PCRX
In the Jun 10 session, PCRX gained 0.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 04 | Proxy reminder | Positive | +0.3% | Company urged votes for its slate, citing revenue records and growth drivers. |
| May 28 | Activist criticism | Negative | -1.5% | DOMA criticized a decade of value destruction and urged board change. |
| May 27 | Support board slate | Positive | -1.5% | Letter highlighting 2025 record revenue, margins and EXPAREL exclusivity. |
| May 27 | Clinical real-world data | Positive | -1.3% | Study showed EXPAREL linked to lower opioid use and healthcare costs. |
| May 26 | IP strategy defense | Neutral | +4.3% | Company addressed DOMA’s statements regarding its IP approach and litigation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed alignment: governance and activism headlines often move the stock, with some positive company updates seeing negative short-term reactions.
Over the last few weeks, Pacira has been in a contested proxy and governance cycle leading up to the June 9, 2026 annual meeting. Management repeatedly promoted its 5x30 strategy, record 2025 revenue and EXPAREL growth, while DOMA criticized long-term value creation and IP strategy. Clinical and real‑world EXPAREL data were also highlighted. Today’s election result follows that campaign, effectively concluding this phase of the proxy contest reflected in prior governance-focused headlines.
Key Terms
proxy solicitor financial
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Frank D. Lee, chief executive officer, said, "On behalf of the board and executive leadership team, I would like to express our appreciation and gratitude to our stockholders for their trust in our team and belief in the future of Pacira. We look forward to continuing to execute across all five pillars of our 5x30 strategy to drive long-term value for patients and stockholders and ensure Pacira is well positioned to sustain its positive momentum well into the future."
These results are preliminary. Final results will be tabulated and certified by the independent inspector of elections and reported on a Current Report on Form 8-K that will be filed with the Securities and Exchange Commission.
Advisors
Goldman Sachs & Co. LLC is acting as financial advisor and Perkins Coie LLP is acting as legal counsel to Pacira.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®°, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Forward-Looking Statements
Any statements in this document about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2026 Annual Meeting of Stockholders; Pacira's board of directors and the contributions of new directors and director nominees; '5x30', our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec) and PCRX-2002; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary high-capacity adenovirus ("HCAd") vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential HCAd-based product candidate; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the "Risk Factors" of Pacira's most recent Annual Report on Form 10-K and in other filings that it periodically makes with the U.S. Securities and Exchange Commission (the "SEC"). In addition, the forward-looking statements included in this document represent Pacira's views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira's views as of any date subsequent to the date of this document.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira's actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the "Risk Factors" of Pacira's most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC.
Contacts
Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com
Media Contact: Kim Hamilton, (973) 254-4644 kim.hamilton@pacira.com
View original content:https://www.prnewswire.com/news-releases/pacira-biosciences-announces-stockholders-have-elected-all-three-of-the-companys-director-nominees-at-annual-meeting-302795858.html
SOURCE Pacira BioSciences, Inc.